Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Directives From House Range From Antibiotics To Zohydro

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft appropriations committee report instructs FDA to undertake tasks both profound (offer a better accounting of how user fees are spent) and routine (meet with patient communities for specific diseases).

You may also be interested in...



Dalvance Approval Is Durata’s GAIN: First Test Of FDA’s Antibiotics Incentives

Durata has honor of having first drug approved under Qualified Infectious Disease Product designation and gains the benefits of an added five years of market exclusivity.

FDA Secure Supply Chain Pilot Draws Small Group, But Could Serve Globalization Goals

Agency planned for up to 100 participants in program allowing expedited entry of some imports, but only approved 13.

Drug Shortage Analysis Puts FDA At Loggerheads With GAO

GAO says ongoing drug shortages are increasing, but FDA says they are flattening; contrasting definitions of “shortage” produce the disparate results.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077262

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel